BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Elevation Oncology, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 4:28 pm Purchase | 2024-09-30 | 13G | Elevation Oncology, Inc. ELEV | BIOTECHNOLOGY VALUE FUND L P | 6,230,845 9.990% | 1,779,960 (+39.99%) | Filing |
| 2024-02-14 10:01 am Purchase | 2023-12-31 | 13G | Elevation Oncology, Inc. ELEV | BIOTECHNOLOGY VALUE FUND L P | 4,450,885 9.990% | 2,138,685 (+92.50%) | Filing |
| 2023-02-13 6:05 pm Purchase | 2022-12-31 | 13G | Elevation Oncology, Inc. ELEV | BIOTECHNOLOGY VALUE FUND L P | 2,312,200 9.900% | 700,502 (+43.46%) | Filing |
| 2022-02-14 1:46 pm Purchase | 2021-12-31 | 13G | Elevation Oncology, Inc. ELEV | BIOTECHNOLOGY VALUE FUND L P | 1,611,698 6.900% | 1,611,698 (New Position) | Filing |